The given clinical review covers current antiviral therapy for chronic hepatitis C. Traditional antiviral therapy with pegylated interferon-alpha and ribavirin in patients with chronic hepatitis C virus genotype 1 allows a sustained virological response (SVR) to be achieved in no more than 40% of the treated patients. The practical introduction of the third component of the therapy as direct-acting antiviral agents makes it possible to substantially increase SVR, on the one hand, and to reduce treatment time, on the other hand.
View Article and Find Full Text PDFThe review considers the chemical structure, pharmacodynamics and pharmacokinetics of telaprevir, a new direct-acting antiviral agent, used to treat patients with chronic hepatitis C (CHC). The given data on Phase II and III clinical trials enable the authors to state the high efficacy of the drug in patients infected with hepatitis C virus type 1. The paper also provides data on the resistance of telaprevir and its drug interaction and denotes the place of the drug in the current antiviral treatment of patients with CHC.
View Article and Find Full Text PDFThe self-association of self-complementary deoxyhexanucleotide d(GCATGC) was investigated in aqueous salt solution. Homonuclear 1H NMR correlation spectroscopy (2D-TOCSY and 2D-NOESY) was used for complete assignments of nonexchangeable protons of the hexamer. The equilibrium reaction constants and thermodynamical parameters of duplex d(GCATGC)2 formation were determined from experimental concentration and temperature dependences of proton chemical shifts of the deoxyhexanucleotide.
View Article and Find Full Text PDFAim: Detection of viral hepatitides markers in patients with alcoholic damage to the liver.
Materials And Methods: Virological, immunological and histochemical tests were performed in 36 chronic alcoholics who had enlarged liver and/or abnormal hepatic characteristics.
Results: 60% of the examinees carried chronic HBV, HCV, HDV infection.